Organoid technology for personalized pancreatic cancer therapy
Bengtsson, Axel LU ; Andersson, Roland LU ; Rahm, Jonas ; Ganganna, Karthik ; Andersson, Bodil LU
and Ansari, Daniel
LU
(2021)
In Cellular Oncology
44(2).
p.251-260
- Abstract
Background: Pancreatic ductal adenocarcinoma has the lowest survival rate among all major cancers and is the third leading cause of cancer-related mortality. The stagnant survival statistics and dismal response rates to current therapeutics highlight the need for more efficient preclinical models. Patient-derived organoids (PDOs) offer new possibilities as powerful preclinical models able to account for interpatient variability. Organoid development can be divided into four different key phases: establishment, propagation, drug screening and response prediction. Establishment entails tailored tissue extraction and growth protocols, propagation requires consistent multiplication and passaging, while drug screening and response prediction... (More)
Background: Pancreatic ductal adenocarcinoma has the lowest survival rate among all major cancers and is the third leading cause of cancer-related mortality. The stagnant survival statistics and dismal response rates to current therapeutics highlight the need for more efficient preclinical models. Patient-derived organoids (PDOs) offer new possibilities as powerful preclinical models able to account for interpatient variability. Organoid development can be divided into four different key phases: establishment, propagation, drug screening and response prediction. Establishment entails tailored tissue extraction and growth protocols, propagation requires consistent multiplication and passaging, while drug screening and response prediction will benefit from shorter and more precise assays, and clear decision-making tools. Conclusions: This review attempts to outline the most important challenges that remain in exploiting organoid platforms for drug discovery and clinical applications. Some of these challenges may be overcome by novel methods that are under investigation, such as 3D bioprinting systems, microfluidic systems, optical metabolic imaging and liquid handling robotics. We also propose an optimized organoid workflow inspired by all technical solutions we have presented.
(Less)
- author
- Bengtsson, Axel
LU
; Andersson, Roland
LU
; Rahm, Jonas
; Ganganna, Karthik
; Andersson, Bodil
LU
and Ansari, Daniel
LU
- organization
- publishing date
- 2021-01-25
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Drug screening, Organoids, Pancreatic cancer, Personalized medicine
- in
- Cellular Oncology
- volume
- 44
- issue
- 2
- pages
- 251 - 260
- publisher
- Springer Science and Business Media B.V.
- external identifiers
-
- pmid:33492660
- scopus:85099949536
- ISSN
- 2211-3428
- DOI
- 10.1007/s13402-021-00585-1
- language
- English
- LU publication?
- yes
- id
- f1fdac5e-e769-4dc2-ae8e-6e183f824269
- date added to LUP
- 2021-02-08 10:06:41
- date last changed
- 2025-03-08 13:17:28
@article{f1fdac5e-e769-4dc2-ae8e-6e183f824269,
abstract = {{<p>Background: Pancreatic ductal adenocarcinoma has the lowest survival rate among all major cancers and is the third leading cause of cancer-related mortality. The stagnant survival statistics and dismal response rates to current therapeutics highlight the need for more efficient preclinical models. Patient-derived organoids (PDOs) offer new possibilities as powerful preclinical models able to account for interpatient variability. Organoid development can be divided into four different key phases: establishment, propagation, drug screening and response prediction. Establishment entails tailored tissue extraction and growth protocols, propagation requires consistent multiplication and passaging, while drug screening and response prediction will benefit from shorter and more precise assays, and clear decision-making tools. Conclusions: This review attempts to outline the most important challenges that remain in exploiting organoid platforms for drug discovery and clinical applications. Some of these challenges may be overcome by novel methods that are under investigation, such as 3D bioprinting systems, microfluidic systems, optical metabolic imaging and liquid handling robotics. We also propose an optimized organoid workflow inspired by all technical solutions we have presented.</p>}},
author = {{Bengtsson, Axel and Andersson, Roland and Rahm, Jonas and Ganganna, Karthik and Andersson, Bodil and Ansari, Daniel}},
issn = {{2211-3428}},
keywords = {{Drug screening; Organoids; Pancreatic cancer; Personalized medicine}},
language = {{eng}},
month = {{01}},
number = {{2}},
pages = {{251--260}},
publisher = {{Springer Science and Business Media B.V.}},
series = {{Cellular Oncology}},
title = {{Organoid technology for personalized pancreatic cancer therapy}},
url = {{http://dx.doi.org/10.1007/s13402-021-00585-1}},
doi = {{10.1007/s13402-021-00585-1}},
volume = {{44}},
year = {{2021}},
}